Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer—an updated systematic review and network meta-analysis

[1] Agarwal M(2019)Cardiovascular effects of androgen deprivation therapy in prostate cancer Curr Oncol Rep 21 91-2986

[2] Canan T(2019)ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer J Clin Oncol 37 2974-1622

[3] Glover G(2022)Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer J Clin Oncol 40 1616-17

[4] Armstrong AJ(2002)Gleason score predicts androgen independent progression after androgen deprivation therapy Eur Urol 42 12-8

[5] Szmulewitz RZ(2018)Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201) Eur Urol 73 4-2303

[6] Petrylak DP(2019)Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy Cells 8 1318-131

[7] Armstrong AJ(2021)Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study J Clin Oncol 39 2294-617

[8] Azad AA(2019)Enzalutamide with standard first-line therapy in metastatic prostate cancer N Engl J Med 381 121-446

[9] Iguchi T(2013)Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials Med Decis Making 33 607-1246

[10] Benaim EA(2017)Global burden of urologic cancers, 1990–2013 Eur Urol 71 437-700

[1] Agarwal M(2019)Cardiovascular effects of androgen deprivation therapy in prostate cancer Curr Oncol Rep 21 91-2986

[2] Canan T(2019)ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer J Clin Oncol 37 2974-1622

[3] Glover G(2022)Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer J Clin Oncol 40 1616-17

[4] Armstrong AJ(2002)Gleason score predicts androgen independent progression after androgen deprivation therapy Eur Urol 42 12-8

[5] Szmulewitz RZ(2018)Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201) Eur Urol 73 4-2303

[6] Petrylak DP(2019)Androgens and androgen receptor actions on bone health and disease: from androgen deficiency to androgen therapy Cells 8 1318-131

[7] Armstrong AJ(2021)Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study J Clin Oncol 39 2294-617

[8] Azad AA(2019)Enzalutamide with standard first-line therapy in metastatic prostate cancer N Engl J Med 381 121-446

[9] Iguchi T(2013)Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials Med Decis Making 33 607-1246

[10] Benaim EA(2017)Global burden of urologic cancers, 1990–2013 Eur Urol 71 437-700